Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Trial Profile

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Carcinoid tumour; Carcinoma; Endometrial cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms KEYNOTE-028
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Results assessing associations between PD-L1 expression and a T-cell inflamed gene expression profile to clinical response in patients with solid tumors from this trial, presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 First results from the carcinoid and pancreatic neuroendocrine tumor cohorts presented at the 42nd European Society for Medical Oncology Congress
    • 09 Aug 2017 Planned End Date changed from 31 Aug 2017 to 13 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top